CML Advocates Network
- Company typePrivate
- Founded2005
- HeadquartersBern, Switzerland
- Headcount1–10
- GTM typeB2B and B2C
- OfferingServices
CML Advocates Network firmographics
Firmographics- Name
- CML Advocates Network
- Legal name
- CML Advocates Network
- Website
- https://cmladvocates.net
- Company type
- Private
- Founded year
- 2005
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Ownership category
- akta.pro rank
Where CML Advocates Network is headquartered
LocationHeadquarters
- HQ city
- Bern
- HQ country
- Switzerland
- HQ region
- Europe
Offices1 record
Markets served
CML Advocates Network business model
Business model- GTM type
- B2B and B2C
- Offering type
- Services
- Cost components
- Personnel, Operations, Marketing or Sales, Technology or R&D, Others
Revenue model
- Donations: The CML Advocates Network accepts donations through its website to support advocacy activities, conferences, and member support programs.
- Sponsorships: CML Horizons conference and other activities are supported through pharmaceutical company sponsorships and industry partnerships. The network publishes acknowledgment pages listing sponsors for each annual conference.
- Membership Dues: Patient organizations join the network as members, potentially contributing membership fees to support the global network's operations.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Freemium | Annual | Free membership for CML patient organizations |
| Other | Annual | CML Horizons Conference Fee |
Go-to-market motion1 record
Distribution channels5 records
Marketing channels11 records
CML Advocates Network product offering
Product offeringCore offering
CML Advocates Network operates a global network of 131 chronic myeloid leukemia (CML) patient organizations across 96 countries, delivering patient and caregiver-led advocacy services. Its core offerings include the annual CML Horizons conference, a Community Advisory Board (CML-CAB) bridging patients with pharmaceutical companies and researchers, multilingual mobile adherence and education apps (CML Today, Know Your CML), the CML-Life free support programme, World CML Day awareness campaigns, and research initiatives such as the Patient Preference Study.
Product overview
CML Advocates Network is a patient and caregiver-led organization serving as a global network of 131 chronic myeloid leukemia (CML) patient organizations from 96 countries. The organization offers a portfolio of advocacy-focused products and services rather than a traditional tech product. Key offerings include the annual CML Horizons Conference (educational conference for patient advocates), the Community Advisory Board (CAB) program facilitating dialogue between patients and pharmaceutical researchers, the Know Your CML mobile app, and CML Life (external support programme). The network provides extensive educational resources including clinical trial databases, ELN recommendations, animated patient videos, and the CML Glossary. Major awareness campaigns include World CML Day (September 22nd) and World Leukemia Day. The organization also conducts research initiatives such as the Patient Preference Study, Big Data program, and treatment-free remission resources. Additional offerings include the Blood Cancer Patient Advocates Academy for training, regional projects, and resources on generic TKIs, COVID-19 specific to CML, and stopping treatment safely.
Differentiator
Problem solved
Functional benefit
Products and services
- CML Horizons Conference Annual international conference bringing together CML patient advocates, healthcare professionals, and industry partners for educational sessions, networking, and knowledge sharing on CML research and advocacy. Includes scholarship support for patient advocates from low-income countries.
- Community Advisory Board (CML-CAB) Global panel of 25 leading patient advocates established in 2016 to provide structured insights and guidance to pharmaceutical companies, regulators, and researchers on CML community needs and treatment access.
- Know Your CML App Mobile application designed to help CML patients track and understand their condition, including treatment monitoring information. Distributed free via app stores to patients globally.
- CML Today (CML Adherence App) Mobile adherence app supporting CML patients in tracking TKI medication intake and PCR results. Available free in multiple languages (English, French, Spanish, German, Portuguese, Arabic, Hebrew) via Apple App Store and Google Play.
- CML-Life Support Programme Free support programme for people affected by CML, including patients, carers, families, and healthcare teams, hosted at cml-life.com.
- Blood Cancer Patient Advocates Academy Educational programme designed to train and empower blood cancer patient advocates in advocacy skills and health equity.
- World CML Day Campaign Annual global awareness campaign held on September 22 (9/22, representing chromosomes 9 and 22) to raise awareness of Chronic Myeloid Leukemia and advocate for patient needs worldwide.
- Patient Preference Study Research initiative studying patient preferences in CML treatment to inform advocacy and healthcare decision-making. Findings have been presented at ASH 2025.
Quantifiable outcome
- 68 photos and 28 stories gathered during World CML Day 2023 campaign, with campaign materials in 12 languages reaching ~40 countries
- +5 more outcomes
Companies that use CML Advocates Network
Customer profileNamed customers3 records
Segments4 records
Ideal customer profiles3 records
CML Advocates Network technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature5 records
CML Advocates Network partnerships and signals
Strategic signalPartnerships
Eleven partnerships are on record, tiered core, major and minor.
- Leukemia Patient Advocates Foundation (LePAF)coreThe Leukemia Patient Advocates Foundation (Stiftung Leukämiepatientenvertreter) serves as the legal host and parent organization of the CML Advocates Network. LePAF is registered with the Chamber of Commerce of the Canton Bern (CH-036.7.052.001-2) and provides the organizational framework within which CMLAN operates. CML Advocates Network is listed under the About page of LePAF (lepaf.org) as one of its patient advocacy initiatives.
- Pharmaceutical Companies (multiple)coreThe CML Advocates Network engages with multiple pharmaceutical companies through its CML-CAB (Community Advisory Board) programme, research collaborations, and conference sponsorships. Annual CML Horizons conferences are sponsored by pharmaceutical companies, with acknowledgments of sponsors published on the network's website. Companies engage with the network to gain patient insights on drug development, clinical trial design, and treatment access strategies.
- American Society of Hematology (ASH)majorCML Advocates Network presents research findings and patient preference data at the ASH Annual Meeting. In December 2025, Jan Geissler presented the network-led poster titled 'Patient Preferences in CML Treatment' at ASH 2025. The network also presented at ASH 2019.
- European Hematology Association (EHA)majorCML Advocates Network participates in EHA Congress annually. In 2026, the network participated in EHA Congress 2026, and together with Acute Leukemia Advocates Network (ALAN) presented new research on psychosocial support needs in CML care. Previously presented at EHA 2020.
- European Group for Blood and Marrow Transplantation (EBMT) Nurses GroupcoreThe EBMT Nurses Group developed the first specialist CML education programme in Europe for nurses. The CML Advocates Network contributed to the creation of the programme and hosts a download form for the CML Learning Programme on its website. The programme contains 4 modules covering understanding CML, CML treatments, managing TKI treatments, and supporting patients living with CML.
- European LeukemiaNet (ELN)coreThe European LeukemiaNet publishes CML treatment recommendations, with the network hosting resources about ELN recommendations on its website. The network actively disseminates and contextualizes ELN recommendations for patients and advocates. New ELN Recommendations 2025 were updated and published July 2025.
- Acute Leukemia Advocates Network (ALAN)majorCML Advocates Network collaborates with the Acute Leukemia Advocates Network on joint research initiatives. In 2026, CMLAN and ALAN together with international collaborators presented new research highlighting the need for greater psychosocial support in CML care at EHA 2026.
- European School of Hematology (ESH)majorCML Advocates Network presented TFR4CML survey results at the European School of Hematology 22nd Annual John Goldman Conference on Chronic Myeloid Leukemia: Biology and Therapy (ESHCML2020).
- International Academy for Clinical Hematology (IACH)majorCML Advocates Network presented an abstract and poster at the IACH 2020 Congress, contributing research on CML patients' concerns and treatment-free remission.
- EURORDIS / Orphanet (European Conference on Rare Diseases)minorCML Advocates Network presented a poster on CML patients' views on psychological support during treatment-free remission at the European Conference on Rare Diseases and Orphan Products (ECRD) 2020, organized by EURORDIS and Orphanet.
- CML Patient Organizations (131 member organizations)core131 CML patient organizations from 96 countries on all continents serve as member organizations of the CML Advocates Network. These organizations access network resources, translate and adapt campaign materials, participate in conferences and CAB meetings, and represent the network at national levels. Members are listed publicly on the network's Members page.
Scale indicators10 records
Recent moves6 records
Expansion highlights5 records
CML Advocates Network competitors and assessment
Company assessmentOthers
- Cancer Support Community: Global nonprofit providing psychosocial support, education, and navigation services to cancer patients and families. Comparable as a complementary, non-disease-specific patient-support organization that operates in adjacent emotional-support and patient-education spaces.
Direct peers
- Acute Leukemia Advocates Network (ALAN): Global network of patient organizations focused on acute leukemias, operating the same membership-network, CAB, and patient-preference model as CML Advocates Network. ALAN and CMLAN have already co-presented research at EHA 2026, making it the closest operational peer.
- Lymphoma Coalition: Worldwide network of lymphoma patient organizations with a global membership model, annual awareness campaigns (World Lymphoma Day), and patient-survey research published at major congresses. Closely analogous in structure, scale, and mission.
- CLL Society: U.S.-based patient advocacy and education organization for chronic lymphocytic leukemia (CLL). Operates a similar disease-specific model combining patient education, advocacy training, expert webinars, and a community advisory function, and is a comparable single-leukemia niche peer.
- International Myeloma Foundation: Global hematology patient advocacy organization running an International Myeloma Working Group and a broad network of patient groups. Highly comparable in combining patient-led advocacy, scientific engagement, and pharmaceutical partnerships in a single hematologic malignancy.
Broad incumbents
- National Organization for Rare Disorders (NORD): U.S. umbrella organization for rare-disease patient groups, providing advocacy training, policy work, and research grants. Operates a similar federation model and serves as a structural peer for national-level rare-disease advocacy.
- European Cancer Patient Coalition: European umbrella of cancer patient organizations active in EU policy, research funding, and advocacy. Comparable as a higher-level federation with overlapping patient-group members and a similar EU-centered stakeholder model.
- The Leukemia & Lymphoma Society (LLS): Large, U.S.-based voluntary health organization funding blood-cancer research and providing patient services across leukemia, lymphoma, myeloma, and other blood cancers. A broad incumbent that overlaps with CMLAN's mission and frequently partners with smaller, disease-specific networks.
- EURORDIS - Rare Diseases Europe:
Emerging players
- GIST Cancer Research Fund / GIST Support International: Dedicated patient advocacy for gastrointestinal stromal tumors (GIST), which originated alongside CML at the same New Horizons conferences in Dublin. A historical and structural peer in a parallel rare-cancer niche.
Market position
Strengths4 records
Competitive moat4 records
Key risks6 records
Key highlights6 records
Customer concentration
CML Advocates Network social profiles
Digital presenceCML Advocates Network financial estimates
Financial estimateRevenue estimate
Valuation estimate
CML Advocates Network leadership team
Management profileNumber of profiles
Profiles4 records
CML Advocates Network funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
CML Advocates Network M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about CML Advocates Network
What does CML Advocates Network do?
CML Advocates Network operates a global network of 131 chronic myeloid leukemia (CML) patient organizations across 96 countries, delivering patient and caregiver-led advocacy services. Its core offerings include the annual CML Horizons conference, a Community Advisory Board (CML-CAB) bridging patients with pharmaceutical companies and researchers, multilingual mobile adherence and education apps (CML Today, Know Your CML), the CML-Life free support programme, World CML Day awareness campaigns, and research initiatives such as the Patient Preference Study.
Is CML Advocates Network a public or private company?
CML Advocates Network is a private company. It is classified as nonprofit foundation owned and is currently operating.
When was CML Advocates Network founded?
CML Advocates Network was founded in 2005. It employs 1 to 10 people.
Where is CML Advocates Network based?
CML Advocates Network is headquartered in Bern, Switzerland, in the Europe region.
How does CML Advocates Network make money?
Three revenue lines are on record. Donations are the primary driver. The others are sponsorships and membership Dues.
Who are CML Advocates Network's main competitors?
Cancer Support Community is listed as an others. Direct peers are Acute Leukemia Advocates Network (ALAN), Lymphoma Coalition, CLL Society and International Myeloma Foundation. Broad incumbents are National Organization for Rare Disorders (NORD), European Cancer Patient Coalition, The Leukemia & Lymphoma Society (LLS) and EURORDIS - Rare Diseases Europe. GIST Cancer Research Fund / GIST Support International is listed as an emerging player.
Does CML Advocates Network have an API?
No public API is recorded for CML Advocates Network.